Nov. 4, 2013
Ventana Medical Systems, Inc. (Ventana)
, a member of the Roche Group, is pleased to announce the positive findings of the Primary ASC-US LSIL Marker Study (PALMS) that have been published in The Journal of the National Cancer Institute.
The pan-European study, including more than 27,000 women from five European countries, was performed to estimate the diagnostic performance of the CINtec®
* cytology test in screening for cervical precancers compared to more traditional screening methods like Pap cytology. The study assessed whether the test, which uses two biomarkers, p16 and Ki-67, that are indicative of oncogenic (cancer-causing) human papillomavirus (HPV) infections, provides both high sensitivity and specificity for high-grade precancerous cervical lesions. The results showed that when compared to Pap cytology testing, the CINtec
cytology test was more effective than Pap cytology in detecting precancerous lesions. Pap cytology had a sensitivity of 67.5% while the CINtec
test had a sensitivity of 86.7%.
"The results of PALMS confirms data from previous studies which have shown that incorporating the CINtec PLUS test in cervical cancer screening programs can provide real benefit to both clinicians and their patients," says Dr. Christine Bergeron, Laboratoire Cerba, Cergy, Paris, France, PALMS study investigator and publication co-author. "In young women, where HPV infection rates may be high, the CINtec PLUS test could be very useful to identify those women with clinically significant precancers who may be missed by the lower sensitivity Pap test. In older women, combining the CINtec PLUS test with HPV DNA testing would make a lot of sense."
More than 500,000 new cases of cervical cancer are diagnosed each year worldwide.
Disappointingly, the average five-year survival rate of patients is only around 50%.
HPV infections are common and cause virtually all cervical cancer.
However, only those women with persistent HPV infections and who have developed high-grade precancerous cervical disease should be treated. The CINtec
cytology test was developed to help identify those HPV infections that may lead to cancer and distinguish them from those that will not.
The authors (Safaeian and Sherman) of an editorial published along with the PALMS study results write that dual biomarker screening could have a role in primary screening, especially in younger women. They also conclude that the dual assay could serve as a triage for positive HPV tests and could dramatically decrease patient referrals to colposcopy and other invasive and costly procedures unnecessarily.